Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia

American Journal Geriatric Pharmacotherapy

Volumn 9, Issue 2, 2011, Pages 133-137

  McDonald, Jaime ^a,b   Corbeil, Philippe ^a,c   Pourcher, Emmanuelle ^b,d  

^a UNIVERSITÉ LAVAL   (Canada)

^b Québec Memory and Motor Skills Disorders Research Center   (Canada)

^c Centre de Recherche du Centre Hospitalier   (Canada)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

levodopa; posture; venlafaxine

Indexed keywords

CARBIDOPA PLUS LEVODOPA; PAROXETINE; VENLAFAXINE;

ADD ON THERAPY; AGED; ARTICLE; BEDTIME DOSAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; FEMALE; HUMAN; LEG; MICROVASCULAR DEMENTIA; PARKINSONISM; PRIORITY JOURNAL; TREATMENT OUTCOME; UROGRAPHY; VASCULAR DISEASE;

AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPARKINSON AGENTS; CYCLOHEXANOLS; DEMENTIA, VASCULAR; DIAGNOSIS, COMPUTER-ASSISTED; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MICROVESSELS; PAROXETINE; POSTURAL BALANCE;

EID: 79955941245     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.03.002     Document Type: Article

References (15)

1. Benatru I, Vaugoyeau M, Azulay JP. Postural disorders in Parkinson's disease. Neurophysiol Clin. 2008;38:459-465.
2. Balaban CD. Neural substrates linking balance control and anxiety. Physiol Behav. 2002;77:469-475. (Pubitemid 36084387)
3. Grimbergen YA, Langston JW, Roos RA, et al. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother. 2009;9:279-290.
4. Woollacott M, Shumway-Cook A. Attention and the control of posture and gait: a review of an emerging area of research. Gait Posture. 2002;16:1-14. (Pubitemid 34786352)
5. Cham R, Perera S, Studenski SA, Bohnen NI. Striatal dopamine denervation and sensory integration for balance in middle-aged and older adults. Gait Posture. 2007;26:516-525. (Pubitemid 47419324)
6. Joo JH, Lenze EJ, Mulsant BH, et al. Risk factors for falls during treatment of late-life depression. J Clin Psychiatry. 2002;63:936-941. (Pubitemid 35231735)
7. Visser JE, Carpenter MG, van der Kooij H, Bloem BR. The clinical utility of posturography. Clin Neurophysiol. 2008;119:2424-2436.
8. Maki BE, Holliday PJ, Fernie GR. Aging and postural control. A comparison of spontaneous- and induced-sway balance tests. J Am Geriatr Soc. 1990;38:1-9. (Pubitemid 20035764)
9. Debonnel G, Saint-André E, Hébert C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neurosychopharmacol. 2007;10:51-61. (Pubitemid 46122752)
10. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747. (Pubitemid 41443048)
11. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects [letter to the editor]. Am J Psychiatr. 1989;146:1352-1353. (Pubitemid 19258488)
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. (Pubitemid 12149145)
13. Baldwin DS, Hawley CJ, Mellors K, for the CN104-070 Study Group. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J Psychopharmacol. 2001;15:161-165. (Pubitemid 32808248)
14. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci. 2010; 289:74-80.
15. Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007;22:1543-1549. (Pubitemid 47477913)